GEN Exclusives

More »

New Products

More »
Jan 1, 2014 (Vol. 34, No. 1)

Enzo Life Sciences

Click Image To Enlarge +

Sclerostin-LRP Interaction Screening System

Leading Light, a chemiluminescent-based binding assay, has been developed to permit the high-throughput screening of sclerostin inhibitors without the need for cell lines or transfection. The assay contains human sclerostin immobilized to a 96-well plate, and uses an engineered LRP5-alkaline phosphatase (AP) conjugate. LRP5-AP binds immobilized sclerostin, producing signal in the development step. Signal decreases when this interaction is blocked by the presence of a sclerostin inhibitor. This system can be used for drug screening to identify small molecule compounds, antibodies, DNA aptamers, and peptides capable of modulating the sclerostin-LRP interaction. Initial screening of sclerostin inhibitors can occur in less than 2.5 hours.

Related To This Company




GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?